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ABSTRACT To evaluate liposome formulations for use as
intracellular sustained-release drug depots, we have compared
the uptake and degradation in rat liver and spleen of liposomes
of various compositions, containing as their bulk phospholipid
an ether-linked phospholipid or one of several ester-linked
phospholipids, by perturbed angular correlation spectroscopy.
Multilamellar and small unilamellar vesicles (MLVs and
SUVs), composed of egg phosphatidylcholine, sphingomyelin,
distearoyl phosphatidylcholine (DSPC), dipalmitoyl phosphati-
dylcholine (DPPC) or its analog dihexadecylglycerophospho-
rylcholine (DHPC), and cholesterol plus phosphatidylserine,
and containing "'In complexed to nitrilotriacetic acid, were
injected intravenously in rats. Recovery of "'In-labeled lipo-
somes in blood, liver, and spleen was assessed at specific time
points after injection and the percentage of liposomes still intact
in liver and spleen was determined by measurement of the
time-integrated angular perturbation factor [G22(o)] of the
"'In label. We found that MLVs but not SUVs, having DHPC
as their bulk phospholipid, showed an increased resistance
against lysosomal degradation as compared to other phospho-
lipid-containing liposomes. The use of diacyl phospholipids
with a high gel/liquid-crystalline phase-transition tempera-
ture, such as DPPC and DSPC, also retarded degradation of
MLV, but not of SUV in the dose range tested, while the rate
of uptake of these liposomes by the liver was lower.
Liposomes have been considered for use as a drug delivery
system for many years (1-3) and have in fact recently entered
the stage of clinical trials for specific applications (4). In
recent years, efforts have been made to optimize the com-
position, size ranges, and other properties of liposomes
relevant for in vivo applications (for a review, see ref. 5).
Although small unilamellar vesicles (SUVs) of appropriate
lipid compositions may be taken up by nonphagocytic cells,
such as hepatocytes (6), the major mechanism of removal of
liposomes from the bloodstream involves endocytosis by the
mononuclear phagocyte system, especially for large lipo-
somes (7-9). This has led to the recognition that liposomes
not only may be considered as a direct drug-delivery system
to diseased target cells but also as a vehicle for the creation
of intracellular drug depots; thus, in cells other than the
ultimate target cells, a sustained release of drug may be
effectuated concomitant with degradation of the drug-
containing liposomes (10, 11). Also, for this type of applica-
tion, the degree of intracellular stability [i.e., resistance to
(intra)lysosomal degradation] becomes an important factor to
consider. Recently, it was found that phospholipids contain-
ing an ether instead of an ester link between the alkyl chain
and the glycerol backbone are highly resistant to metabolic
conversion (12, 13). It has been suggested that such phos-
pholipids may be used to prepare liposomes with an increased
resistance to intralysosomal degradation (14).
An attractive method to measure the integrity of liposomes
in blood, cells, or even in a whole organ or animal, without
the need to recover the liposomes from the system, is
perturbed angular correlation (PAC) spectroscopy (15, 16).
The angular correlation of the two y-rays emitted upon the
decay of "'In to 1"'Cd provides information on the tumbling
rate of this ion. The high tumbling rate of "'In, chelated in the
interior of liposomes [high time-integrated angular perturba-
tion factor, G22(oo)], decreases upon breakdown of the
liposomes and the subsequent release of "'In because of the
rapid binding of the ion to macromolecules in the surrounding
solution. Thus, the fraction of liposomes in the sample that is
still intact can readily be measured (15-18).
In view of the possible use of liposomes as an intracellular
slow-release drug depot system, we used the PAC spectros-
copy technique to compare the in vivo rates of degradation in
liver and spleen of liposomes of different compositions. We
examined the uptake and degradation of both SUVs and
multilamellar liposomes (MLVs) of the same compositions.
The SUVs were previously shown to be mainly directed to
the hepatocytes and the MLV were directed predominantly
to the liver macrophages (Kupffer cells) (7-9). All the
liposome types. investigated contained 50% cholesterol
(Chol) to enhance stability in serum (19, 20) and 10%
phosphatidylserine (PS) to provide them with a negative
charge to prevent aggregation. The balance of the lipid (40%)
consisted of either phosphatidylcholine (PC) or beef brain
sphingomyelin (SM) or dihexadecylglycerophosphorylcho-
line (DHPC), an ether-linked analog ofdipalmitoyl phosphati-
dylcholine (DPPC), that was reported to be resistant to
intracellular degradation (12-14) and also to increase the
stability of liposomes in serum (21, 22).
MATERIALS AND METHODS
Materials. Egg phosphatidylcholine (egg PC), distearoyl
phosphatidylcholine (DSPC), and DPPC were purchased
from Avanti. Chol (type CH-S), bovine brain PS, bovine
brain SM, nitrilotriacetic acid (NTA), Sephadex G-25-50,
and Hepes were from Sigma. DHPC was from Bachem
(Bubendorf, Switzerland). Carrier-free indium-111 was pur-
chased from Amersham.
Liposomes. For the preparation of liposomes, aliquots of
stock solutions in chloroform/methanol (4:1) of either egg
Abbreviations: Chol, cholesterol; DHPC, 1,2-dihexadecyl-
sn-glycero-3-phosphorylcholine; DPPC, dipalmitoyl phosphatidyl-
choline; DSPC, distearoyl phosphatidylcholine; egg PC, egg phos-
phatidylcholine; MLV, multilamellar vesicle; NTA, nitrilotriacetic
acid; PAC, perturbed angular correlation; PS, phosphatidylserine;
SM, sphingomyelin; SUV, small unilamellar vesicle.
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PC, DSPC, DPPC, DHPC, or SM; Chol; and PS were mixed
in a molar ratio of 4:5:1. The solvent was evaporated under
a stream of N2, whereupon the lipid film was dissolved in
cyclohexane and lyophilized. The dried lipid was then hy-
drated with 1 mM NTA in HN buffer (10mM Hepes/135 mM
NaCl, pH 7.4) and vigorously mixed in a Vortex to form
MLVs. For preparation of SUVs, this liposome suspension
was sonicated for 60 min with a Branson sonicator (type
W225R) equipped with a microtip probe (20% output power)
at room temperature or, for DPPC-, DHPC-, and DSPC-
containing liposomes, at 50'C. The resulting optically clear
SUV suspension was centrifuged for 15 min at 10,000 x g to
remove probe-derived titanium particles and residual MLVs
and then chromatographed on a Sephadex G-25-50 column
equilibrated in HN buffer to remove nonencapsulated NTA.
MLVs were prepared by lyophilizing appropriate amounts
of lipids from cyclohexane and hydrating the dry lipid with 1
mM NTA in HN buffer, as with the SUV preparation
procedure. After vigorous Vortex mixing, the suspension
was extruded successively through 0.8- and 0.4-gm polycar-
bonate membranes (Nuclepore). Extrusion of DPPC- and
DHPC-containing MLVs was done above their phase-
transition temperatures by immersing the extrusion cell in a
50'C water bath.
To load the liposomes with the radioactive probe, 10 ACi(1 Ci = 37 GBq) of carrier-free 11'In HCO per ,umol of total
liposomal lipid was taken to dryness under a heat lamp and
rehydrated with 30 ,ul of HCl (3 mM) plus 0.5 ml of a 15 mM
acetylacetone solution in Tris buffer [10 mM Tris-
(hydroxymethyl)-aminomethane/145 mM NaCl, pH 7.6]. To
this solution, 2 ml of liposome suspension was added and the
mixture was incubated for 60 min at room temperature for the
egg PC- and SM-containing vesicles, at 37°C for the DPPC-
and DHPC-containing vesicles, and at 50°C for the DSPC-
containing vesicles. In this protocol, the presence of the
ionophore acetylacetone allows the "'1In to traverse the
liposomal membrane, whereupon it is chelated in the lipo-
somal interior by the encapsulated NTA. This procedure
results in an 1"'In entrapment efficiency of >80% (23).
Nonencapsulated 1"'In, acetylacetone, and Tris buffer were
removed by passing the liposomes over a Sephadex G-25-50
column equilibrated with HN buffer.
Animal Experiments. Eight male Sprague-Dawley rats
(190-220 g) per liposome preparation were injected intrave-
nously under light ether anesthesia with 4 ,umol of liposome
suspension (total liposomal lipid) in 0.5 ml of HN buffer via
the penis vein. At 1, 6, 12, and 24 hr after injection, the rats
were killed. Blood samples were taken by cardiac puncture,
the livers were excised after perfusion through the portal vein
with 60 ml ofphosphate-buffered saline, and the spleens were
extirpated. To determine the amount of liposomes remaining
in the blood, we assumed a total blood volume per rat of6.5%
body weight. In the measurements of total organ radioactiv-
ity, the decay of "1'In was taken into account.
From each rat, =1 ml of blood, 1 g of liver tissue, and the
spleen were used immediately to determine the absolute 1"'In
uptake and the time-integrated angular perturbation factor
[G22(oo)] (17, 18) on the PAC spectrometer at room temper-
ature. To correlate this G22(oo) factor to the percentage intact
liposomes, the G22(oo) values of liposomes in HN buffer (0.59
± 0.02) and of carrier-free "'In in bovine serum (0.19 ± 0.02)
were assumed to represent 100% and 0% intact liposomes,
respectively.
RESULTS
To assess the solute retention capacity of the liposome
preparations in serum, the release of "'In was monitored for
4 days at 37°C (Fig. 1) as a decrease in the time-integrated
angular perturbation factor G22(oo), which is equivalent to a
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FIG. 1. Serum-induced leakage of liposomes. SUVs (100 ,ul, 1.0
Amol) were added to 100 ,ul of rat serum and incubated at 37°C. At
the time points indicated, the time-integrated angular perturbation
factor G22(oo) was determined, from which the percentage intact
vesicles was calculated. Data represent mean of four incubations.
Liposome compositions: X/Chol/PS = 4:5:1, where X is egg PC (o),
SM (o), DSPC (x), DPPC (A), or DHPC (A).
decrease in the percentage intact vesicles. As appears from
Fig. 1, the resistance of SUVs to serum-induced leakage is
strongly dependent on the type of phospholipid used, even in
the presence of equivalent amounts of Chol. The use of
phospholipids with high gel/liquid-crystalline phase-
transition temperatures like DSPC, DPPC, and DHPC [phase-
transition temperatures, 53.7°C, 40.6°C, and 42.8°C, respec-
tively (24)] clearly favor good solute retention in serum. This
is in good agreement with conclusions reached previously
(25).
Fig. 2 shows the disappearance from blood of "'In after
intravenous injections of "'In-labeled SUVs. Of all types of
SUVs used, the major fraction is cleared from the blood-
stream within 6 hr, although there were slight differences in
the elimination rates of the various liposome types tested.
SUVs containing phospholipids with higher phase-transition
temperatures, such as DSPC, DPPC, and DHPC, are cleared
less rapidly from the bloodstream than those containing lower
phase-transition temperature phospholipids, like egg PC and
SM.
The liver uptake of SUVs was inversely correlated with
blood elimination (Fig. 3A). The egg PC-containing liposomes
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FIG. 2. Blood elimination of SUVs. Male Sprague-Dawley rats
were injected intravenously in the penis vein with 2 ,umol of
"'In-labeled SUVs per 100 g of body weight. The rats were killed 1,
6, 12, and 24 hr after injection and a sample of =1 ml of blood was
taken from the heart and radioactivity was determined. Total
radioactivity remaining in blood was estimated by assuming a total
blood volume of 6.5% of the rat's body weight. Each time point
represents the average value of two rats. Liposome compositions:
X/Chol/PS = 4:5:1, where X is egg PC (o), SM (o), DSPC (x), DPPC
(A), or DHPC (A).
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FIG. 3. Uptake and degradation of SUVs in the liver. Rats were
injected intravenously with 2 ,tmol of "'In-labeled SUVs per 100 g
of body weight and killed 1, 6, 12, and 24 hr after injection. The liver
was perfused with 50 ml of cold PBS, excised, weighed, and cut into
small pieces. Total radioactivity and the time-integrated angular
perturbation factor G22(oo) were determined in a liver tissue sample
of -1 g, within 1 hr after death of the animal. From these data, the
total liposome uptake (A) and the percentage intact liposomes (B) in
the liver were calculated. Time points represent averages oftwo rats.
Liposome compositions: X/Chol/PS = 4:5:1, where X is egg PC (e),
SM (a), DSPC (x), DPPC (A), or DHPC (A).
especially were taken up relatively rapidly, reaching maximal
amounts in the liver only 1 hr after injection of the liposomes.
The DSPC-, DPPC-, and DHPC-containing SUVs did not
reach maximal uptake values until 12 hr after injection. For
all these liposome types, the liver-associated fraction de-
creased between 12 and 24 hr after injection. No difference
in liver uptake was observed between the DHPC- and
DPPC-containing SUVs.
Fig. 3B shows the percentage of intact vesicles in the liver.
For DHPC-, DPPC-, and SM-containing SUVs this is only
-30% within the first hour after injection. For egg PC and
DSPC-containing SUVs, however, the fraction of intact
vesicles is =70% after 1 hr and decreases to 30% between 1
and 6 hr after injection. Between 6 and 24 hr after injection,
the proportion of intact vesicles in the liver further decreases
only very slowly for all SUV types tested.
Liposome uptake is much lower in the spleen than in the
liver (Fig. 4). Clearly, the liposome types that were taken up
the least avidly by the liver-i.e., DSPC-, DPPC-, and
DHPC-containing SUVs-showed the highest uptake by the
spleen. This may be due to the increased spillover from the
liver under these circumstances. The percentage of intact
vesicles in the spleen varied between 30% and 50% at 1 hr
after injection and decreased gradually in the following 24 hr
for all liposome preparations (Fig. 4B).
As shown in Table 1, the total recovery of liposomal label
Table 1. Percentage total recovery label in blood, liver,
and spleen
Time after injection, hr
1 6 12 24
Egg PC 92 80 79 71
SM % 79 64 78
DPPC 84 64 65 54
DHPC 88 66 76 56
DSPC 92 74 73 63
Rats were injected intravenously with 2 ,umol of "'In-labeled
SUVs per 100 g ofbody weight and sacrificed 1, 6, 12, and 24 hr after
injection, at which time total recovery of radioactivity in liver,
spleen, and blood was determined. Results are averages of two rats.
FIG. 4. Uptake and degradation ofSUVs in the spleen. Rats were
injected intravenously with 2 ,umol of "1'In-labeled SUVs per 100 g
ofbody weight and killed 1, 6, 12, and 24 hr after injection. The spleen
was excised and weighed. Total radioactivity and the time-integrated
angular perturbation factor G22(oo) were then determined in the intact
spleen. From these data, the total liposome uptake (A) and the
percentage intact liposomes (B) in the spleen were calculated. Time
points represent averages of two rats. Liposome compositions:
X/Chol/PS = 4:5:1, where X is egg PC (o), SM (o), DSPC (x), DPPC
(A), or DHPC (A).
in liver, spleen, and blood decreases from between 84% and
96% at 1 hr to between 54% and 71% of the injected dose at
24 hr after injection.
We do not consider it very likely that the extensive initial
release of "1in reflects a proportional chemical degradation
of the liposomes in view of our earlier observations on the
metabolic conversion of liposomal lipids (26). Physical dis-
turbance-e.g., due to extensive interaction of the liposomal
membranes with (lysosomal) proteins-is probably more
likely to cause the rapid initial release of 1"'In. The results of
experiments with MLVs are compatible with this latter view.
Since MLVs contain several concentric bilayers and as many
aqueous compartments, complete release ofthe encapsulated
"'1In would require the consecutive degradation of all lipid
bilayers.
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FIG. 5. Uptake and degradation of MLVs in the liver. Rats were
injected intravenously with 2 ,umol of "1'In-labeled MLVs per 100 g
of body weight and killed 1, 6, 12, and 24 hr after injection. The liver
was perfused with 50 ml of cold PBS, excised, weighed, and cut into
small pieces. Total radioactivity and the time-integrated angular
perturbation factor G22(oo) were determined in a liver tissue sample
of -1 g. From these data, the total liposome uptake (A) and the
percentage intact liposomes (B) in the liver were calculated. Time
points represent averages of two rats. Liposome compositions:
X/Chol/PS = 4:5:1, where X is egg PC (e), SM (o), DPPC (A), or
DHPC (A).
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FIG. 6. Uptake and degradation of liposomes in the spleen. Rats
were injected intravenously with 2 ,umol of "'In-labeled MLVs per
100 g of body weight and killed 1, 6, 12, and 24 hr after injection. The
spleen was excised and weighed. Total radioactivity and the time-
integrated angular perturbation factor G22(oo) were then determined
in the intact spleen. From these data, the total liposome uptake (A)
and the percentage intact liposomes (B) in the spleen were calcu-
lated. Time points represent averages of two rats. Liposome com-
positions: X/Chol/PS = 4:5:1, where X is egg PC (e), DPPC (A), or
DHPC (A).
Fig. 5 presents the liver uptake (Fig. 5A) and degradation
(Fig. SB) of various types of injected MLVs. Only 1 hr after
injection, maximal liver uptake is attained, in contrast to the
more slowly eliminated SUVs. Egg PC-containing MLVs are
taken up more avidly by the liver than either DPPC- or
DHPC-containing vesicles. Similar to what we observed for
the SUVs, we noticed also for MLVs a gradual decrease in
total label content, particularly of the liver. Also, with
respect to intracellular degradation, the egg PC liposomes
show a higher rate of degradation than either the DPPC or the
DHPC liposomes (Fig. 5B). During the first hour after
injection, 10-35% of the encapsulated "'In is released in the
liver. From then on, label release proceeds more gradually
with average rates between 3.0%/hr for DSPC and 0.4%/hr
for DHPC during the first 24 hr. The slower phase of the label
release presumably reflects metabolic degradation of the
liposomes, while the rapid initial phase is probably mostly
accounted for by physicochemical effects on the outermost
bilayer. The DHPC MLVs are apparently more resistant to
breakdown than DPPC MLVs. One day after their uptake by
liver cells, only 35% of the "'In label has leaked from the
DHPC MLVs, whereas 60% has been released from the
DPPC MLVs. After 2 days, these values are 55% and 70%,
respectively.
In the spleen, the uptake of egg PC-containing MLVs is
much lower than that of DHPC- or DPPC-containing MLVs
(Fig. 6A). Also, in this organ, just as in the liver, the DHPC
MLVs appear to be the most stable liposome type (Fig. 6B).
In addition, there is an initial rapid release of "'In in the first
hour after injection of the liposomes, followed by a second
phase of slower release.
DISCUSSION
In recent years, the preparation of stable liposomal slow-
release drug-delivery systems has drawn much attention. The
use of ether-linked phospholipids to create stable liposomes
was suggested several years ago (14). More recently, the use
of polymerizable liposomes has also been considered as an
alternative strategy for the preparation of liposomes that are
resistant to degradation (27-29). However, thus far no studies
have been published showing an increased solute retention
capacity for polymerized as compared to normal liposomes,
and reports dealing with ether phospholipid liposomes mainly
focus on the extension of the circulatory half-life and in-
creased resistance against serum-induced degradation (14,
21, 22). None of these reports, however, has examined the
actual intracellular stability of these liposomes.
One method to assess the integrity of liposomes involves
the relief of self-quenching of carboxyfluorescein encapsu-
lated in liposomes in high concentrations (>30 mM). The
observed increase in fluorescence upon leakage of the car-
boxyfluorescein from the liposomes is a measure of the
fraction of the liposomes degraded (30). Although this
method is very convenient for measuring liposome stability in
buffer and serum, it is less suitable for measuring intracellular
liposome breakdown. The use of PAC spectroscopy, on the
other hand, has in recent years proven to be a reliable method
to simultaneously assess uptake and degradation of lipo-
somes in whole organs and even in small animals, without the
need for prior tissue homogenization or label extraction.
Hence, this technique was chosen to examine the in vivo
disposition of liposomes in our studies.
The PAC technique requires that the liposomes contain a
relatively large amount of '11In (10 ACi per ,mol of liposomal
lipid). This high entrapment efficiency could be achieved by
loading the liposomes that contained NTA as a chelator in
their aqueous compartments with the ionophore acetylace-
tone (23). Having established first that the liposome compo-
sitions used showed no significant leakage of the "1In-NTA
complex upon storage for several days in HN buffer at 40C,
we then proceeded to measure the liposomal "1In release
upon incubation in rat serum at 370C. Even though there was
a substantial loss of encapsulated "1'In from some liposome
preparations (as much as 30% for egg PC/Chol/PS SUVs)
after 24 hr of incubation in rat serum, this is probably
irrelevant with respect to our in vivo liposome uptake results.
Firstly, it is unlikely that much "1'In had leaked from the
liposomes during their stay in the circulation, since the
liposomes of all compositions used were cleared so fast that
within 6 hr after injection the blood compartment was
virtually devoid of 1"'In label. Secondly, the percentage of
intact vesicles in the blood, as measured by the G22(oo)
parameter, was consistently higher than 90%, indicating that
the leakage of "'In from the liposomes in our experiments is
low indeed. Thirdly, preliminary experiments showed that
nonentrapped "'In had a half-life in blood of -3 hr, with the
"'In appearing rapidly in the urine. Since the recovery of
"'In label in blood, liver, and spleen amounted to at least 80%
of the injected dose during the first uptake phase, not much
"'In could have escaped from the body during the time the
liposomes were in circulation. Therefore, we feel confident
that virtually all the "'In remained associated with the
liposomes until their uptake by the target cells.
From our results we conclude that, in spite of the reported
resistance of DHPC toward lysosomal degradation, in par-
ticular against the action of phospholipase A2 (12, 13), the use
of this lipid instead of its ester analog DPPC for the prepa-
ration of SUVs does not lead to an increase of intracellular
liposomal stability. As was shown, the blood disappearance
as well as the uptake by liver and spleen and the in vitro serum
stability were similar for both the DHPC- and DPPC-
containing SUVs. Also, the rate of degradation, as reflected
in the percentage intact liposomes in liver and spleen, did not
differ appreciably. In MLVs, however, the use of DHPC as
a bulk phospholipid instead of DPPC substantially improved
the intracellular stability ofthese liposomes. Both in liver and
in spleen, DHPC-containing MLVs were the most stable
liposomes tested.
There may be several reasons why the stabilizing effect of
DHPC was so much more apparent for MLV than for SUV.
Firstly, the degradative capacity of the liver for the types of
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SUV tested may be so high that with the liposome doses used
no differences in rates of liposome breakdown could be
established. Only in the case of a very rapid uptake of large
quantities of liposomes, as was the case with the egg PC
liposomes, did the liver show any signs of saturation of the
liposome degradation capacity. Although a large fraction of
the injected dose is still intact in the liver, the total amount
of liposomes degraded in the liver is high. We also observed
this saturation of liposome degradation in the liver for other
liposome compositions at high dose ranges (unpublished
observation).
Secondly, MLVs are taken up almost exclusively by the
Kupffer cells (7, 8) whereas SUVs of the compositions used
predominantly end up in the hepatocytes (6). Thus, an
intrinsic difference in degradative capacity between these
two cell types could also contribute to a difference in
intracellular liposome breakdown. In addition, the number of
hepatocytes is -10 times that of Kupffer cells, which implies
that the amount of lipid taken up per cell is much higher for
MLVs than for SUVs. Thus, the intracellular mechanism of
liposome degradation may be more likely to become satu-
rated in the case of MLVs than in the case of SUVs.
Thirdly, the difference in intracellular stability between
SUVs and MLVs is likely to be related to the difference in the
number of aqueous compartments per vesicle. An instanta-
neous nonchemical destabilization of the membrane of SUVs
due to protein-lipid interactions would rapidly release all
encapsulated '11In. A similar destabilization of the outermost
membrane of aMLV would lead to the release of only a small
fraction of the encapsulated 1"'In, the remainder being
released from the inner compartments only upon gradual
chemical degradation of the consecutive inner lamellae. The
initial rapid release of -30% of the entrapped '11In for both
the DHPC and DPPC MLVs (Figs. 5 and 6) would seem to
support this explanation if it is assumed that 30% represents
the label contained in the outermost aqueous compartment
(31).
We observed that the radioactivity recovered in the liver as
well as in the spleen reaches a maximum between 6 and 12 hr
after injection of the SUVs, and within 1 hr for the MLVs.
The subsequent decrease in radioactivity reflects an organ
redistribution of the label as indicated by the accumulation of
radioactivity in the kidneys and at later time points in the
urine. No 1"'In label was excreted in the bile (data not
shown). We also noticed that the G22(oo) value is low in the
kidney but high in the urine. The "'In secreted by the liver
cells into the bloodstream after intrahepatic degradation of
the liposomes is probably bound to protein, giving rise to a
low G22(oo) value. In the kidneys, the "'In is stripped from
the protein, as a result of which the tumbling rate increases
[high G22(oo) value]; it is later excreted into the urine.
In conclusion, the use of ether-linked phospholipids offers
an advantage over the ester-linked equivalent in terms of
increased liposome stability in the case of MLVs but not of
SUVs. DHPC-containing MLVs may be useful as a sus-
tained-release drug-delivery system, especially for drugs
exerting their therapeutic effect in the liver. After uptake and
degradation of such drug-loaded MLVs by Kupffer cells, the
entrapped drug may then be released by the cells, thus
providing sustained drug availability..
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